Avacta Group Plc · LSE:AVCT
Avacta — H1 2013 Earnings Presentation
19 slides from Avacta's earnings presentation, Apr 30, 2013
Slide 1: Avacta Group plc Interim Results Presentation
Avacta Group plc ! Innovation for global health! Interim Results Presentation ! 30th April 2013!
Slide 2: Avacta Group plc
Avacta Group plc Technology, consumables and reagents for life sciences! ! Avacta Analytical ! Avacta Animal Health! Avacta Life Sciences! Technology for In-clinic veterinary Reagents and tools biopharma developers! diagnostics and services! life sciences! © Avacta Group plc! 2!
Slide 3: Avacta's Market Opportunity
Avacta’s Market Opportunity Technology, consumables and reagents for Life Sciences! ! Antibody replacement reagents! Disruptive drug and biomarker discovery technology! Antibody Replacement Technology! Risk! Protein stability analysis High margin instrumentation! £100m pa*! OPPORTUNITY! Veterinary D
Slide 4: Analytical Division: Interim Results
Analytical Division : Interim Results Performance impacted by transition to new product and distributor! Advanced protein analytics supporting bio-therapeutic developers! • Over 40 units now shipped! • Slow half year sales (2 units) in line with expectation due to distributor changes (Forte Bio) and
Slide 5: Analytical Division: Outlook
Analytical Division : Outlook Poised to reap benefits of Optim2 and ForteBio partnership! • Commercial partnership with ForteBio team strengthening! • Further improvements to consumable margin planned for summer 2013 ! • Number of applications and reference sites growing rapidly! • Full year will be
Slide 6: Animal Health Division: Interim Results
Animal Health Division : Interim Results Revenues hold firm despite recessionary pressure on vet practices! Established veterinary diagnostics reference laboratory business with good growth potential through launch of AX-1 Sensipod in-clinic blood analyser and test kits! • Half year sales revenue £7
Slide 7: Animal Health Division: Outlook
Animal Health Division : Outlook Sensipod test menu expansion! • Good progress on expanding the test menu as commercial launch of the in-clinic analyser approaches! • Tests well advanced in development:! – Canine/feline allergy screens! – Canine/feline/equine acute phase protein tests! – Canine/feli
Slide 8: Results for the 6 Months Ended 31-01-2013: Income Statement
Results for the 6 Months Period Ended 31-01-2013 Consolidated income statement! Unaudited Unaudited Audited 6 months to 6 months to Year ended 31 January 2013 31 January 2012 31 July 2012 £000 £000 £000 Avacta Animal Health revenue 730 725 1,488 Avacta Analytical revenue 420 992 1,642 Total revenue
Slide 9: Consolidated cash flow statement
Results for the 6 Months Period Ended 31-01-2013 Consolidated cash flow statement! Unaudited Unaudited Audited 6 months to 6 months to Year ended 31 January 2013 31 January 2012 31 July 2012 £000 £000 £000 Operating cash flow before changes in working capital (801) (324) (1,259) Movement in working
Slide 10: Consolidated balance sheet
Results for the 6 Months Period Ended 31-01-2013 Consolidated balance sheet! Unaudited Unaudited Audited As at 31 January As at As at 31 January2013 2012 31 July 2012 £000 £000 £000 Non-current assets Intangible assets 12,973 11,253 12,095 Property, plant & equipment 903 376 636 Income taxes 150 - -
Slide 11: Affimers
Affimers! Antibody replacement technology!
Slide 12: The Antibody Market
The Antibody Market The most widely used affinity reagent with multiple large markets! • Antibodies are naturally occurring proteins capable of capturing specific targets. They have been harnessed very widely for research, diagnostic, and therapeutic applications! Academic, pharmaceutical, industria
Slide 13: Avacta's Antibody Replacement Technology
Avacta’s Antibody Replacement Technology The “Affimer” protein scaffold! Affimers technically could replace antibodies in all their markets but are more likely to become a very valuable binding surface complementary tool ! • Affimers have a binding surface to capture a specific target just like an a
Slide 14: Current Commercial Plans
Current Commercial Plans Focus on reagent supply and disruptive drug discovery technology ! Avacta is currently focusing its resources in two commercial applications of Affimers :! • Reagents! – High quality, robust alternatives to antibodies! • Protein microarrays! – World’s largest affinity microa
Slide 15: Affimer Reagents' Competitive Advantages
Affimer Reagents’ Competitive Advantages 10-100x cheaper than antibodies, faster to develop and technically superior! Affimers! Antibodies! Other Non- DNA/RNA antibody Proteins! Aptamers! Cost of Easy and cheap Expensive to Varies but some Easy and cheap Production! to produce; with produce and are
Slide 16: Reagents Commercial Strategy
Reagents Commercial Strategy Compete on quality; partner with established routes to market! • Market drivers! – Technical, quality and supply difficulties with antibodies! – Diagnostics, therapeutics and R&D demanding superior reagents! • Product positioning! – High quality, no batch to batch variab
Slide 17: Affimer Arrays: Disruptive Proteomic Tools
Affimer Arrays : Disruptive Proteomic Tools The world’s largest protein microarrays for drug and biomarker discovery! 20k – 100k different Affimers per array Healthy sample applied Diseased sample applied an printed onto a standard glass slide! to an array, incubated, identical array, incubated, the
Slide 18: Arrays Commercial Strategy
Arrays Commercial Strategy Initial focus on R&D market to drive downstream companion diagnostics! • Market drivers! The largest – Huge pressure from regulators to develop companion diagnostics! an$body microarray, the – Biomarker discovery essential and currently challenging! Panorama Array from Sig
Slide 19: Avacta Group: Summary
Avacta Group : Summary Strong equity growth opportunity underpinned by revenue generating businesses! • In-clinic veterinary AX-1 Sensipod analyser in final stages of production and test menu expansion progressing well! • Slow half year sales of Optim2 slow due to distributor changes and product upg